Literature DB >> 8072083

Unusual neoplasms detected in testis cancer patients undergoing post-chemotherapy retroperitoneal lymphadenectomy.

J S Little1, R S Foster, T M Ulbright, J P Donohue.   

Abstract

Approximately 30% of patients with disseminated testis cancer who receive platinum-based chemotherapy will experience normalization of tumor markers but have persistent, radiographically evident disease in the retroperitoneum. These patients usually undergo retroperitoneal lymph node dissection. Of 557 patients undergoing post-chemotherapy retroperitoneal lymph node dissection at our university medical center 45 (8.1%) had neoplastic elements distinct from the classical germ cell tumor types within the resected specimens. Examples include various sarcomas in 19 patients (3.7%), other nonsarcomatous nongerm cell cancers in 18 (3.2%) and cystic atypical choriocarcinoma in 8 (1.4%). No distinct patient characteristics or histological patterns in the primary tumor are predictive of these unusual findings in the retroperitoneal lymph node dissection specimen, although sampling error in the orchiectomy specimen could be the reason for this lack of correlation. Surgical resection of these chemoresistant tumors is potentially curative, with disease-free survival in 13 of 19 patients (68.4%) with sarcoma, 10 of 18 (55.6%) with nonsarcomatous cancer and 7 of 8 (87.5%) with cystic atypical choriocarcinoma at a mean followup of 30.6, 42.5 and 24.7 months, respectively.

Entities:  

Mesh:

Year:  1994        PMID: 8072083     DOI: 10.1016/s0022-5347(17)32524-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

Review 1.  Teratoma with somatic-type malignant components of the testis. A review and an update.

Authors:  Gregor Mikuz; Maurizio Colecchia
Journal:  Virchows Arch       Date:  2012-05-24       Impact factor: 4.064

2.  Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series.

Authors:  Claudio De Vito; Debashis Sarker; Paul Ross; Nigel Heaton; Alberto Quaglia
Journal:  Virchows Arch       Date:  2017-07-13       Impact factor: 4.064

Review 3.  Therapeutic strategies for uncommon testis cancer histologies: teratoma with malignant transformation and malignant testicular sex cord stromal tumors.

Authors:  Mounsif Azizi; Ahmet M Aydin; Salim K Cheriyan; Charles C Peyton; Matthew Montanarella; Scott M Gilbert; Wade J Sexton
Journal:  Transl Androl Urol       Date:  2020-01

Review 4.  Biology of metastases and its clinical implications: testicular germ-cell tumors.

Authors:  J P Donohue; R S Foster; J S Little; P J Loehrer; L E Einhorn
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

5.  Somatic malignant transformation in a sacrococcygeal teratoma in a child and the use of F18FDG PET imaging.

Authors:  R Howman-Giles; A J A Holland; D Mihm; J M Montfort; S Arbuckle; S Kellie
Journal:  Pediatr Surg Int       Date:  2007-09-09       Impact factor: 1.827

6.  Management of poor-prognosis testicular germ cell tumors.

Authors:  Kiranpreet Khurana; Timothy D Gilligan; Andrew J Stephenson
Journal:  Indian J Urol       Date:  2010 Jan-Mar

7.  Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer.

Authors:  Joseph A Pettus; Brett S Carver; Timothy Masterson; Jason Stasi; Joel Sheinfeld
Journal:  Urology       Date:  2008-11-20       Impact factor: 2.649

8.  [Regression of germ cell tumors after chemotherapy].

Authors:  V Loy; U Klenk; J Linke
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

9.  Teratoma with malignant transformation: a case report with pathological, cytogenetic, and immunohistochemistry analysis.

Authors:  Jue Wang; Syed A Jaffar Kazmi
Journal:  Sarcoma       Date:  2011-06-09

10.  DNA topoisomerase I and II expression in drug resistant germ cell tumours.

Authors:  D M Berney; J Shamash; J Gaffney; S Jordan; R T D Oliver
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.